Mayne Pharma presentation at HC Wainwright Conference in NY
Released
Released
Announcement PDF
ASX Announcement
MAYNE PHARMA TO PRESENT AT THE H.C. WAINWRIGHT
25TH ANNUAL GLOBAL INVESTMENT CONFERENCE
11 September 2023, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) today announced
that Shawn Patrick O’Brien, Chief Executive Officer of Mayne Pharma, will present at the H.C.
Wainwright 25th Annual Global Investment Conference in New York City as follows:
Date:
Time:
Webcast:
Monday, September 11, 2023
9:00am US Eastern Time
Click here
A copy of the presentation slides is attached.
For further information contact:
Australia:
Craig Haskins
+61 421 029 843
ir@maynepharma.com
USA:
Lisa M. Wilson
T: 917-543-9932
E: ir@maynepharma.com
Authorised for release to the ASX by the Chair
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel
pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides
contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40- year track
record of innovation and success in developing new oral drug delivery systems. These technologies have been
successfully commercialised in numerous products that continue to be marketed around the world. To learn
more about Mayne Pharma, please visit maynepharma.com.
Mayne Pharma
Group Limited
ASX:MYX
HC Wainwright Healthcare Conference
September 11, 2023
Shawn Patrick O’Brien, CEO
1
Disclaimer
The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s Preliminary
Financial Report and other market disclosures. This material is not intended to be relied upon as advice to investors or potential investors.
Non-IFRS information
● Other than as indicated, the financial information contained in this document is directly extracted or calculated from the Preliminary Financial Report
which is subject to completion of the Auditor’s Review. Throughout this document some non-IFRS financial information is stated, excluding certain
specified income and expenses. Results excluding such items are considered by the Directors to provide a meaningful basis for comparison from period to
period.
● Earnings before interest, tax, depreciation and amortisation (EBITDA) – a non-IFRS term – is considered by Directors to be a meaningful measure of the
operating earnings and performance of the Group and this information may be useful for investors.
● The non-IFRS financial information has not been audited by the Group’s auditors.
Forward looking statements
● This presentation contains forward-looking statements that involve subjective judgement and analysis and are subject to significant uncertainties, risks and
contingencies, many of which are outside the control of, and are unknown to the Company. These forward looking statements use words such as
‘potential’, ‘expect’, ‘anticipate’, ‘intend’, ‘plan’, ‘target’ and ‘may’, and other words of similar meaning. No representation, warranty or assurance (express
or implied) is given or made in relation to any forward looking statement by any person (including the Company). Actual future events may vary materially
from the forward looking statements and the assumptions on which the forward looking statements are based. Given these uncertainties, readers are
cautioned not to place undue reliance on such forward looking statements. Subject to the Company’s continuous disclosure obligations at law and under
the listing rules of the Australian Securities Exchange, the Company disclaims any obligation to update or revise any forward looking statements. The
factors that may affect the Company’s future performance include, among others: changes in economic conditions, changes in the legal and regulatory
regimes in which the Company operates, litigation or government investigations, decisions by regulatory authorities including approval of our products as
well as their decisions on label claims, competitive developments affecting our products, changes in behaviour of major customers, suppliers and
competitors, interruptions to manufacturing or distribution, acquisitions and divestitures, the success of research and development activities and research
collaborations and the Company’s ability to protect its intellectual property.
Other
● A glossary of industry terminology is contained in the Mayne Pharma Annual Report which can be accessed at maynepharma.com/investorrelations/results-reports and product descriptions are detailed at maynepharma.com/us-products and maynepharma.com/au-products.
● ANNOVERA®, BIJUVA®, IMVEXXY®, NEXTSTELLIS®, ORACEA® and VITAMED® are trademarks of third parties.
2
FY23 Performance Highlights
Refocused on core businesses and reset capital structure
✓ Completed sale of Metrics Contract Services and US Retail Generics for a combined sale price of US$565m
✓ Created scale in US Women’s Health business via TXMD transaction1
✓ Transformed balance sheet – net cash of $176.2m (vs FY22 net debt $317m), with conservative position maintained
through transformation process whilst delivering prudent capital management of $46.7m special dividend and onmarket buyback up to 10%
Growth/improvement across all segments
✓ BPD/Women’s Health – strong revenue growth following relaunch of NEXTSTELLIS® and from 2HFY23 launch of
women’s health portfolio products. Significant improvement in segment gross profit and direct contribution in
2HFY23 (positive on underlying basis)
✓ PPD/Dermatology – delivered significant 2HFY23 turnaround in revenue and gross margin following poor 1HFY23
performance with new commercial discipline to rebase business targeting sustainable and profitable growth
✓ International – revenue, gross profit and direct contribution growth delivered in 2HFY23 through CDMO activity.
Commenced business improvement program to improve plant efficiency and secure international CDMO growth
Improved Financial Performance
✓ Delivered revenue growth in 2HFY23 across all segments to $131.5m (1HFY23: $52.1m). 2HFY23 gross profit increased
to $66.6m (1HFY23: $16.9m) and positive direct contribution of $0.9m (1HFY23: negative direct contribution of $42.7m)
✓ Generated positive operating free cash flow of $14.1m in 2HFY23
(1) Acquired from TherapeuticsMD Inc (TXMD) the exclusive license to commercialise a portfolio of on-market women’s health products including three patent protected novel women’s health
products: ANNOVERA®, IMVEXXY® and BIJUVA® and a portfolio of prenatal vitamins.
3
Mayne Pharma at a Glance
Capitalising on commercial opportunities across three attractive business units
Putting the right people, products, and processes in place to address the needs of patients and
drive long-term sustainable growth in each of our three segments
Branded Products (Women’s Health)
Portfolio Products (Dermatology)
One of the top 2 specialised women’s
health companies in the US1
Sales team of 100 located throughout
the continental US
Mayne Pharma portfolio is capable of filling
1 in 3 US Dermatology Retail Rx’s2
Sales team of 47 in continental US
Reproductive Health
• Flagship product
NEXTSTELLIS®
• ANNOVERA® and
vitaMedMD® licensed in
December 2022
Menopause Management
• BIJUVA® and IMVEXXY®
licensed in December 2022
•
•
Speciality brands
(Cosette, Upsher-Smith,
Torrent, GALDERMA, Sandoz, Encube)
Patients
Process
Proprietary brands
(FABIOR®, SORILUX®, DORYX®, LEXETTE®)
•
20+ generic dermatologics
International
•
CDMO
•
Australian Products
•
International Products
(1) Based on size of US Women’s Health Commercial Operations calling on OB/GYNs (2) IQVIA recent 12-month TRx totals by molecule
4
FY24 Outlook
Positive momentum continues into FY24
✓ Completion and integration of FY23 transactions
✓ Another year of focused execution
✓ All three business units delivering positive contribution margins
✓ Return Company to positive EBITDA in FY24
Women’s Health
•
•
•
Dermatology
International
NEXTSTELLIS®
breakeven run rate in
1HFY241
•
Add accretive products
•
•
Execute pilot for
channel strategy
New leadership driving
operational excellence
•
BIJUVA® low strength
launch
•
Pricing adjustments to
improve NSP
Business development
to grow revenues
•
Grow licensed
contraceptive and
menopause product
revenues
•
Targeted investment
to improve site
productivity and
capability
Positive profit and
contribution FY24
1. Breakeven is defined as gross margin equivalent to direct OPEX on an annualised basis
5
Group Financial Overview
•
Results are presented from continuing operations to exclude Metrics Contract Services (MCS) which was divested on 4 October 2022 and to
exclude the US Retail Generics business (previously included in the Portfolio Products (PPD) segment) which was divested on 7 April 2023. The
results include adjustments to reflect movements to adjust FY22 results to a comparable basis.
•
Group Revenue up 17% as growth in BPD (NEXTSTELLIS® and contribution from portfolio of women's health products licenced under the exclusive
licencing agreement with TXMD 31 December 2022) and International business exceed decline in PPD (dermatology).
•
Increase of reported Gross Profit is offset by a decline in margin to 45.5% vs 50.1% in FY22 reflecting challenges in PPD (dermatology)
•
Reported EBITDA loss reflects higher operating expenses to support future growth
•
Reported Net Loss after tax includes $215.4m expenses therein $134.7m related to depreciation & amortisation and asset (primarily intangibles)
impairments, $47.7m income tax expense, $28.8m finance expenses primarily discount unwind on earnouts.
A$ million1
FY23
FY22
Change
Reported Revenue
$183.6
$157.1
$26.5
Reported Gross Profit
$83.5
$71.6
$11.9
Reported EBITDA
($102.0)
$9.0
($111.0)
Reported Net Loss After Tax
($317.4)
($220.1)
($97.3)
Underlying EBITDA2
($95.3)
($59.6)
($35.7)
1. Attributable to members. EBITDA excludes asset impairments.
2. Refer to FY22 Results Presentation for adjustments to underlying EBITDA
6
Segmental Performance
Refocused business delivering improved momentum and positive contribution in 2H
Reported results (A$m)
Revenue
Portfolio Products
Branded Products
International
Total
Operating expenses
- Dermatology
1
- Other
Portfolio Products
Branded Products
International
Total
1HFY23
2HFY23
FY23
FY22
11.1
13.4
27.6
52.1
45.9
48.5
37.1
131.5
57.0
61.9
64.7
183.6
92.2
10.6
54.4
157.1
Gross profit
Portfolio Products
Branded Products
International
Total
14.4
3.1
17.5
36.0
6.1
59.6
13.9
0.1
14.1
45.6
6.0
65.6
28.3
3.3
31.6
81.6
12.1
125.3
23.7
1.5
25.2
55.1
9.6
89.9
Direct Contribution
- Dermatology
- Other
Portfolio Products
Branded Products
International
Total
1HFY23
2HFY23
FY23
FY22
-2.6
10.7
8.8
16.9
13.3
43.2
10.1
66.6
10.7
53.9
18.9
83.5
45.4
8.4
17.7
71.6
-17.0
-3.1
-20.1
-25.4
2.8
-42.7
-0.7
-0.1
-0.9
-2.3
4.1
0.9
-17.7
-3.3
-21.0
-27.6
6.9
-41.8
21.7
-1.5
20.2
-46.6
8.1
-18.3
All three business units improved on revenue, gross profit and direct contribution 2H vs. 1H
1. Other within PPD represents Adelaide Apothecary
7
Cost adjustments delivering some results – more work to do
● FY23 OPEX without mitigating measures
would total $194.4M
● Cost savings focus delivers $5.8M in FY23
8
Reducing costs to enable investment in growth
FY23 costs
added(2)
FY23 costs
added(2)
(3.5%)*
FY23
reduction
realized
(5.5%)* (2.0%)*
FY24
reduction
in process/
budgeted
FY24
investment(3)
Further
FY24
reduction
planned
● FY23 investments:
- $16.9m NEXTSTELLIS® DTC + AU
launch
- $18m TXMD
- $4.5m disintermediation
- $39.4m TOTAL
● Cost reduction program delivers $5.8m
savings FY23 effective.
● Cost reductions FY24 targeted at $10.5m
FY22
Operating
Expense (1)
FY23
Operating
Expense (1)
Marketing & Distribution
Ongoing Admin (1)
FY24 Cost
Basis
R&D and Reg Affairs
● Remainder to be targeted $3.5m &
beyond
* As a percent of total FY2023 operating expense
(1) Excludes amortization and one-time costs.
(2) Marketing & Distribution: NEXTSTELLIS® launch costs and investments in Adelaide Apothecary (PPD) to support disintermediation strategy
Administrative: FX translation, professional fees, increase share-based payment, IT charges
R&D and regulatory affairs: women’s health portfolio support
(3) Marketing & Distribution: Investing to support the expanded WH business (BPD): growth in sales team and marketing initiatives (incl DTC and sampling) under refreshed strategy
Administrative: salary increases, biostudies investment, ERP
R&D and regulatory affairs: medical affairs
9
Branded Products Division (BPD)
Women’s Health
Women’s Health / Branded Products Division (BPD)
FY23 highlights
● Segment performance reflects 2HFY23 contribution from licensed WH
products as well as improved performance of NEXTSTELLIS® following
refreshed marketing strategy.
● NEXTSTELLIS® FY23 revenue US$14.1m with 2HFY23 in line with 1HFY23. Net
revenues depressed by one-time accounting change and development of
charges to revenue (experience with actuals following
introduction). However, expectations around path to profitability are
holding.
A$million
1H23
2H23
FY23
FY22
Reported revenue
13.4
48.5
61.9
10.6
Reported Gross Profit
10.7
43.2
53.9
8.4
Gross Profit %
80%
89%
87%
80%
Direct operating expense
36.0
45.6
81.6
55.1
Direct contribution
(25.4)
(2.3)
(27.6)
(46.6)
● Women’s health expansion portfolio revenue US$24.4m in 2HFY23 unit sales and demand in line with plan. Net revenues depressed by onetime accounting change negatively impacted sales by US$5.7m, adjusting for
this, revenue was US$30.1m.
2%
5% 3%
7%
34%
● Adjusting for one off accounting changes, Direct Contribution of
US$4.7m would have been achieved, which is aligned with outlook provided
in May.
20%
FY2023
Revenue
Contribution
● Women’s health expansion products generated positive operating cash flow
in 2HFY23.
● Costs well managed to support growth in sales team and marketing
expenses (DTC campaign, sampling).
29%
NEXTSTELLIS
ANNOVERA
IMVEXXY
TOLSURA
SOLTAMOX
Vitamins
BIJUVA
11
Nextstellis - Net Sales Price Illustration
Co-pay change
Government
Fes
Medicaid
Managed care
Actions to improve NSP
Co-Pay rules
Others Impacting GTN
Cash discounts
Chargebacks
Chargebacks Pipeline
Returns
FFS
Co-Pay Misuse reduction
Via Rise-Rx
Manage Care
Plus Possible ACA Impact
12
NEXTSTELLIS® Update
● Monthly cycle count increased to 33,100 in July 2023 (+2.5x from July 2022)
● Unit sales growth of 267% on FY22 – total units of 256,330 for FY23
● Growth of prescriptions through improved commercial effectiveness and efficiency
NEXTSTELLIS® monthly cycles
Cycle totals based on IQVIA Exponent Data adjusted for non-reporting pharmacies through 31Jul23
13
Women’s health expansion portfolio update
● Women’s health expansion portfolio is delivering to expectation in demand units (scripts)
● Momentum building into FY24 as investment in sales and marketing is gaining traction in the menopause
including targeting specialist HCPs
ANNOVERA® Units
IMVEXXY® Units
BIJUVA® Units
Unit totals based on IQVIA Exponent Data adjusted for non-reporting pharmacies through 31Jul23
14
Portfolio Products Division (PPD)
Dermatology
Portfolio Products Division (PPD) - Dermatology
FY23 highlights
● 2HFY23 sales reflecting improved sales as inventories normalised and
pricing stabilised
A$million
1H23
2H23
FY23
FY22
Reported revenue
11.1
45.9
57.0
92.2
● Continued conservative approach to co-pay methodology
Reported Gross Profit
(2.6)
13.3
10.7
45.4
● Disciplined cost performance reflecting active brand management
to maximise contribution
Gross Profit %
-24%
29%
19%
49%
Direct operating expense
17.5
14.1
31.6
25.2
● Successful launch of DORYX® MPC 60
Direct contribution
(20.1)
(0.9)
(21.0)
20.2
● gORACEA® launch underperformed due to unplanned channel
inventories
16
Disintermediating the Pharmaceutical Value Chain
Pharmaceutical Value Chain
The pharmaceutical value chain is filled with
inefficiencies and pain points
Plan Sponsor
• Multiple stakeholders with opposing financial interests cause
inefficiencies, higher costs, lack of transparency, and lack of trust
• PBMs are incentivised by rebates and the top 3 control 80% of
the market, resulting in higher costs to consumers, fewer choices
for prescribers, and margin pressures for manufacturers
Manufacturer
• Purchasing alliances control >95% of the market and
manufacturer bargaining power is limited
HCP/Prescriber
• Consumers face high prices and coverage uncertainty and don’t
trust online offerings which are difficult to navigate
• Prescribers/HCPs seek reduced administrative burden, greater
choice in patient treatment, and simpler patient access to
minimise abandonment and promote adherence
Wholesaler
Pharmacy
Patient
THE GOAL: Help patients receive quality drugs quickly and at the best price while
increasing prescriber efficiency and customer satisfaction.
17
Disintermediation Strategy
Mayne Pharma’s unique platform spans the entire value chain, allowing for the ability to create a
comprehensive, frictionless, transparent, and cost-effective experience
Why Dermatology?
✓ There is great desire for
disintermediation in the industry,
with the Dermatology segment a
logical starting point
✓ Most dermatological conditions are
not permanently cured, resulting in
ongoing demand/continuous refills
✓ Long cycle times for treatment
✓ Conditions are non-acute and
patients are more willing to wait for
shipping and shop online
✓ Insurance coverage is poor and
getting worse
Why Mayne Pharma?
130 territory
representatives
>60% of
prescribing activity
✓ Drug sourcing ability:
• Mayne Pharma portfolio is capable of
filling 1 in 3 US Dermatology Retail Rx(1)
• Access to wholesalers and intermediary
platforms
• Established relationships with Bx & Gx
manufacturers
Manufacturer
✓ Pharmacy network allows for
HCP/Prescriber
consistent product availability,
choice, and pricing:
• Adelaide Apothecary for cash-pay claims,
licensed to operate in 50 states
• 400+ specialty pharmacy locations and
partnerships for reimbursed claims
✓ Extensive provider/customer
Wholesaler
Pharmacy
Patient
coverage:
• 145+ field representatives
• Reach of 50k+ prescribers in targeted
therapeutic areas, covering >60% of
prescribing activity
1. IQVIA recent 12-month TRx totals by molecule
18
International
International
FY23 highlights
● Solid progress as new management team commenced business
improvement initiatives at Salisbury manufacturing facility including
product throughput efficiency, procurement initiatives and building
International business development opportunities
● $12m investment in partnership with the Australian Government who
provided an $4.8m grant under their Modern Manufacturing Initiative
(MMI) program improves capabilities and efficiencies in the Salisbury
facility
● CDMO revenues increased >50% on FY22 largely attributable to new third
party contract sales in 2H following divestment of US Retail Generics
● MPA revenues increased 7% on FY22 with in licensed product growth of
26% attributable to new product launches and growth in existing product
portfolio
A$million
1H23
2H23
FY23
FY22
Reported revenue
27.6
37.1
64.7
54.4
Reported Gross Profit
8.8
10.1
18.9
17.7
Gross Profit %
32%
27%
29%
33%
Direct operating expense
6.1
6.0
12.1
9.6
Direct contribution
2.8
4.1
6.9
8.1
● Continued progress in growing Opioid Substitution Therapy (OST)
opportunities in Europe in International Products
● Year on year cost increase reflects NEXTSTELLIS® launch costs and
additional sales and marketing to support Australian market entry – sales
performance to plan, costs well managed in 2HFY23
20
Strategy for Growth
Addressing the needs of patients across 3 segments while driving sustainable profitability and growth
Near term initiatives
Patients
Broaden Women’s Health and Dermatology
portfolios, leveraging sales infrastructure and
distribution platforms
Global market forecast to grow by 19% per annum to
reach US$35B in 2031
Continue to find ways to disintermediate the
traditional supply chain via alternate channels
(DTC, specialty pharmacies, Good Rx)
Process
USA
Dermatology pricing refinements to drive
improved contribution
Drive International performance with new
contracts and markets
Women’s
Health
Dermatology International
21
Business Outlook and Priorities for FY24
● The Company expects to complete integration of the licensed women’s health assets in FY24 with a focus on
growth and improving net selling prices. The Company is pursuing a growth strategy with the expected launch of
low strength BIJUVA® and by leveraging our salesforce scale and effectiveness. For NEXTSTELLIS® the Company is
targeting a breakeven1 run rate in 1HFY24, with continued growth throughout FY24.
● For Dermatology, the Company plans to continue to enter into capital light, accretive business arrangements and
drive commercial excellence in FY24. We are further developing our channel strategy and leveraging our ability
to drive market share to expand partnerships. Improved profitability is a clear objective for the Dermatology
business.
● For International, the Company is pursuing targeted investment and new manufacturing revenue streams. The
Company plans to continue to drive specialty and generic product sales including driving growth in NEXTSTELLIS®
in Australia and will continue to invest in a targeted manner in the Salisbury facility to improve our productivity
and capabilities.
● With all 3 business units contributing positive contribution margin, the Company expects to return to positive
EBITDA and operating cash generation in FY24.
1. Breakeven is defined as gross margin equivalent to direct OPEX on an annualised basis
22
Q&A
Mayne Pharma
Group Limited
ASX:MYX
You deserve tomorrow.
23
Share your feedback
Discover